Results 21 to 30 of about 13,452 (195)
Radioimmunotherapy: A novel treatment of non-Hodgkin lymphoma [PDF]
Archive of Oncology, 2010 90Y-ibritumomab tiuxetan (Zevalin) and 131I-tositumomab (Bexxar) are current choices for radioimmunotherapy (RIT) of patients with follicular rituximab-relapsed or refractory CD20+ follicular B-cell NHL.
Petrović Tomislav, Mihailović Jasna
doaj +1 more source
Perspectives on metals-based radioimmunotherapy (RIT): moving forward
Theranostics, 2021 Radioimmunotherapy (RIT) is FDA-approved for the clinical management of liquid malignancies, however, its use for solid malignancies remains a challenge.
J. White +2 more
semanticscholar +1 more source
Fate of 177Lu-CHX-A”-DTPA-Rituximab: In vitro Evaluation in Raji Cell Line
Journal of Radiation and Cancer Research, 2023 Context: Radioimmunotherapy is an emerging treatment modality for various types of cancers. While immunotherapy using monoclonal antibodies has shown promising results, particularly in hematological malignancies, a significant number of patients develop ...
Saloni Arun Samant +2 more
doaj +1 more source
Current concepts of 131I therapy in oncology: Indications, methods and follow up [PDF]
Archive of Oncology, 2006 Radioiodine in various forms (as sodium iodide and as the iodinated compounds MIBG, LIPIODOL, et al.) has been used as a therapeutic agent in oncology. Differentiated thyroid carcinoma (DTC) has been successfully treated by 131I therapy.
Mihailović Jasna
doaj +1 more source
Frontiers in Oncology, 2013 Radioimmunotherapy has demonstrated efficacy with acceptable toxicity leading to approval in non-Hodgkin’s lymphoma, but has been slower to develop for the treatment of advanced solid tumors.
Scott T Tagawa +11 more
doaj +1 more source
Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials
Cancers, 2021 Simple Summary Monoclonal antibody-bearing radionuclides have been under clinical investigation over the last two decades for their use in theranostic (diagnostic and therapeutic) applications in cancer.
Aurélie Rondon, J. Rouanet, F. Degoul
semanticscholar +1 more source
Experimental Hematology & Oncology, 2012 Background Repeated administration of antibody-based therapies such as radioimmunotherapy depends on preserved antigen expression in tumor lesions. The purpose of this study was to evaluate whether the antigen expression in metastases observed after ...
Elgström Erika +4 more
doaj +1 more source
Narrative review of emerging roles for AKT-mTOR signaling in cancer radioimmunotherapy
Annals of Translational Medicine, 2021 Objective To summarize the roles of AKT-mTOR signaling in the regulation of the DNA damage response and PD-L1 expression in cancer cells, and propose a novel strategy of targeting AKT-mTOR signaling in combination with radioimmunotherapy in the era of ...
Changxian Shen +6 more
semanticscholar +1 more source
Pharmaceuticals, 2021 Background: Osteosarcoma (OS) has an overall patient survival rate of ~70% with no significant improvements in the last two decades, and novel effective treatments are needed.
Jaline Broqueza +8 more
doaj +1 more source
Haematologica, 2008 Background The study aimed to evaluate FDG-PET imaging for early prediction of response to radioimmunotherapy in patients with non-Hodgkin’s lymphoma.Design and Methods Twenty-seven patients from a large ongoing, multicenter, phase I/II trial of ...
Caroline Bodet-Milin +10 more
doaj +1 more source